Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Malignancy interleukin-2 treatment

Aldesleukin is a recombinant form of human Interleukin-2 (IL-2). It has been approved for the treatment of malignant melanoma and renal cell cancer. The medicine is administered every 8 hours by a 15-minute intravenous infusion for a maximum of 14 doses. Adverse reactions include hypo- and hypertension, gastrointestinal disturbances, fever, fatigue, lethargy, joint pain, headache. Cardiovascular problems may occur. [Pg.461]

Interferon and interleukin 2 (IL-2) are used in the treatment of malignant melanoma, renal cell... [Pg.250]

Massarotti EM, Liu NY, Mier J, Atkins MB. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 1992 92(6) 693-7. [Pg.69]

O Day SJ, Agarwala SS, Naredi P, Kass CL, et al. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma a detailed safety analysis. Melanoma Res 2003 13 307-311. [Pg.2539]

Rhines LD, DiMeco F, Lawson HC, Tyler BM, Hanes J, Olivi A, Brem H. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy A novel treatment for experimental malignant glioma. Neurosurgery 2003 52 1-8. [Pg.375]

Jacobs SK, Wilson DJ, Komblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma phase I trial. Cancer Res 1986 46 2101-2104. [Pg.518]

Holladay FP, Heitz T, Chen YL, Chiga M, Wood GW. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 1992 31 528-533. Kitahara T, Watanabe O, Yamaura A, Makino H, Watanabe T, Suzuki G et al. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol 1987 4 329-336. [Pg.520]

Astoul P, Picat-Joossen D, Viallat J, Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma a Phase II study. Cancer 1998 83 2099-2104. [Pg.317]

See other pages where Malignancy interleukin-2 treatment is mentioned: [Pg.41]    [Pg.604]    [Pg.1421]    [Pg.69]    [Pg.41]    [Pg.1320]    [Pg.88]    [Pg.47]    [Pg.604]    [Pg.1844]    [Pg.1847]    [Pg.211]    [Pg.660]    [Pg.182]    [Pg.369]    [Pg.346]    [Pg.1619]    [Pg.1868]    [Pg.181]    [Pg.310]    [Pg.332]    [Pg.509]    [Pg.320]   
See also in sourсe #XX -- [ Pg.664 ]



SEARCH



Interleukine

Interleukines

Malignancy

Malignant

© 2024 chempedia.info